The Pulmonary Hypertension Comprehensive Care Center at NewYork-Presbyterian/Morgan Stanley Children's Hospital is one of the largest in the world. Established over 20 years ago, the Center is committed to the treatment of both adults and children with pulmonary hypertension, a serious condition which can occur at any age and affects the smallest blood vessels in the lungs. Children who come to us for their care receive treatment from a program that features:
- National Accreditation: NYP/Morgan Stanley Children's Hospital is fully accredited as a Center of Comprehensive Care by the Pulmonary Hypertension Association's Pulmonary Hypertension Care Centers program. These Centers strive to improve the overall quality of care and outcomes in patients with this life-threatening disease. Through this accreditation, we have established our commitment to providing excellence in pulmonary hypertension care.
- A Team of Experts: As a Pulmonary Hypertension Care Center, we ensure that your child's health is managed by highly trained and specialized physicians and other healthcare professionals who have demonstrated a dedication to both the care of people with pulmonary hypertension as well as the larger scientific community studying this disorder. Your child can receive all of the care he or she needs in one hospital.
- The Latest Treatments: We'll customize a treatment plan tailored to your child's needs. Treatment may include medications for pulmonary hypertension. We also have exceptional experience performing extracorporeal membrane oxygenation (ECMO) in children with pulmonary hypertension. ECMO is a device that functions as an artificial lung to support a child's own failing lungs, and it is not widely available at many other hospitals.
- Education and Guidance: Education of patients and their families is a high priority for us. Our staff of doctors and nurses is readily available to educate and support your child and your family.
- A Commitment to Research: Our team members remain on the forefront of research to advance the field. In fact, our Center has participated in most of the pivotal clinical trials to date for the development of new medical treatments for pulmonary hypertension, including the first drug approved for treatment of this condition in 1995. Our research team is currently participating in several clinical trials of novel medications to treat pulmonary arterial hypertension. Your child may have an opportunity to participate in a clinical trial of a promising new therapy.